Pfizer Inc. closed $8.04 short of its 52-week high ($36.94), which the company achieved on August 29th.
Investors seeking safe dividend stocks may consider pharmaceutical giant Pfizer, which looks like a great passive ...
The Food and Drug Administration announced Thursday it has greenlighted updated COVID-19 vaccines from Pfizer and Moderna for the 2024 fall season. The decision clears the way for distribution to ...
We upgraded the rating for Pfizer (PFE) stock, citing positive trends within the company and in the market, despite recent drop after Q2 earnings. Learn more here.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But ...
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and ...
Chris Boshoff, top oncology executive, counts on gains from the $43 billion Seagen merger.
Berenberg Bank analyst Kerry Holford maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $27.00. The company’s shares closed yesterday at $28.78. According to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results